Salicylic Acid

Salicylic Acid

SCHEMBL980591

O=C(O)c1ccccc1O.[GaH3]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHE

The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.95
KDM4E B2RXH2 6/20 0.95
HPGD P15428 6/20 0.95
SMN1; SMN2 Q16637 2/20 0.95
CA12 O43570 2/20 0.95
CA1 P00915 2/20 0.95
CA2 P00918 2/20 0.95
CA7 P43166 2/20 0.95
CA9 Q16790 2/20 0.95
CA14 Q9ULX7 2/20 0.95
HMGB1 P09429 1/20 0.95
CA4 P22748 1/20 0.95
CA6 P23280 1/20 0.95
NAPRT Q6XQN6 1/20 0.95
ALOX15 P16050 2/20 0.65
HSD17B10 Q99714 4/20 0.59
MAPT P10636 3/20 0.58
TSHR P16473 2/20 0.58
G6PD P11413 1/20 0.58
CASP7 P55210 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicylic Acid SCHEMBL980590 1.00 ALDH1A1 (0.95) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL17156443 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL29362663 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL1509155 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL1967 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL29606432 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL29360246 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL8433746 0.97 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Salicylic Acid SCHEMBL546853 0.95 ALDH1A1 (0.95) ALDH1A1KDM4EHPGDSMN1; SMN2CA12
Phthalic Acid SCHEMBL1162068 0.95 ALDH1A1 (0.95) ALDH1A1KDM4EHPGDSMN1; SMN2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116344842-A Carbon-supported low-platinum alloy nanocrystalline catalyst, preparation method and application thereof, and fuel cell 北京化工大学 2023-06-27 CN claimed
EP-2658895-B1 ALKYLENE OXIDE POLYMERIZATION USING A DOUBLE METAL CYANIDE CATALYST COMPLEX AND A MAGNESIUM, GROUP 3-GROUP 15 METAL OR LANTHANIDE SERIES METAL COMPOUND DOW GLOBAL TECHNOLOGIES LLC (US) 2021-06-23 EP claimed
US-10233284-B2 Alkylene oxide polymerization using a double metal cyanide catalyst complex and a magnesium, group 3-group 15 metal or lanthanide series metal compound DOW GLOBAL TECHNOLOGIES LLC (US) 2019-03-19 US claimed
US-20170101506-A1 ALKYLENE OXIDE POLYMERIZATION USING A DOUBLE METAL CYANIDE CATALYST COMPLEX AND A MAGNESIUM, GROUP 3 - GROUP 15 METAL OR LANTHANIDE SERIES METAL COMPOUND DOW GLOBAL TECHNOLOGIES LLC 2017-04-13 US claimed
US-20140031328-A1 Gallium compounds and methods of use to treat inflammatory bowel disease BERNSTEIN LAWRENCE RICHARD (US) 2014-01-30 US claimed
US-20110021484-A1 Gallium compounds and methods of use to treat inflammatory bowel disease BERNSTEIN LAWRENCE RICHARD 2011-01-27 US claimed
EP-2262509-A2 GALLIUM COMPOUNDS AND METHODS OF USE TO TREAT INFLAMMATORY BOWEL DISEASE Bernstein, Lawrence (US) 2010-12-22 EP claimed
WO-2009111681-A2 GALLIUM COMPOUNDS AND METHODS OF USE TO TREAT INFLAMMATORY BOWEL DISEASE BERNSTEIN LAWRENCE (US) 2009-09-11 WO claimed
EP-4423168-B1 POLYETHER POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-12-10 EP disclosed
EP-4638556-A1 ALKOXYLATION PROCESSES USING PHOSPHORUS AND DOUBLE METAL CYANIDE CATALYSTS Dow Global Technologies LLC (US) 2025-10-29 EP disclosed
US-20250115711-A1 POLYETHER POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-04-10 US disclosed
US-12201971-B2 Polyether polymerization process DOW GLOBAL TECHNOLOGIES LLC (US) 2025-01-21 US disclosed
US-20240392068-A1 POLYETHER POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES LLC (US) 2024-11-28 US disclosed
US-12152104-B2 Polyether polymerization process DOW GLOBAL TECHNOLOGIES LLC (US) 2024-11-26 US disclosed
EP-2262509-A2 GALLIUM COMPOUNDS AND METHODS OF USE TO TREAT INFLAMMATORY BOWEL DISEASE Bernstein, Lawrence (US) 2010-12-22 EP disclosed
WO-2009111681-A2 GALLIUM COMPOUNDS AND METHODS OF USE TO TREAT INFLAMMATORY BOWEL DISEASE BERNSTEIN LAWRENCE (US) 2009-09-11 WO disclosed
EP-0242693-B1 ANTIFOULANTS FOR THERMAL CRACKING PROCESSES PHILLIPS PETROLEUM COMPANY (US) 1990-08-29 EP disclosed
US-4804487-A ORGANIC GALLIUM AND/OR TIN COMPOUNDS PREVENT FORMATION OF CARBON DEPOSITS PHILLIPS PETROLEUM COMPANY (US) 1989-02-14 US disclosed
EP-0242693-A1 Antifoulants for thermal cracking processes PHILLIPS PETROLEUM COMPANY (US) 1987-10-28 EP disclosed
US-4666583-A COMPOUNDS OF GALLIUM WITH TIN OR ANTIMONY PHILLIPS PETROLEUM COMPANY (US) 1987-05-19 US disclosed